Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sunitinib + temozolomide
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of sunitinib, a multi-targeted receptor tyrosine kinase inhibitor with anti-angiogenic properties, and temozolomide, an alkylating agent. This combination has been investigated primarily for the treatment of gliomas, including glioblastoma multiforme. The combination works through sunitinib's inhibition of VEGFR, PDGFR, and KIT receptors to reduce tumor angiogenesis, while temozolomide damages DNA through alkylation, leading to cell death. Studies have shown that simultaneous administration yields better tumor control than sequential treatment or monotherapy with either agent.
- Other names
- temozolomide + SU11248
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)DNAFLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sunitinib + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sunitinib + temozolomide.